Floatz logo

Paliperidone Palmitate 3-Month Formulation

Stimulant Abuse

The University of Hong KongPhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Stimulant Abuse cohort.

Asset / SponsorPhaseRating
Seroquel®
Boston Medical Center
Phase 4BBB
Seroquel®
Boston Medical Center
Phase 4BBB
Risperdal
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Opc-34712
University of Massachusetts, Worcester
Phase 4BB
17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL
University of Texas Southwestern Medical Center
Phase 4BB

View all 27 →

Same molecule, other indications

Paliperidone Palmitate 3-Month Formulation is also rated in:

schizoaffective disorderDormant
BBB
Indicative ·
78 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
76 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →